Working… Menu

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) (CARMEN CD 306)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03566823
Recruitment Status : Terminated (Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.)
First Posted : June 25, 2018
Last Update Posted : March 15, 2021
Information provided by (Responsible Party):
Takeda ( Shire )

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : August 18, 2020
Actual Study Completion Date : August 18, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 16, 2021